Skip to content
IRONXPEPTIDES
NAD+ 100MG research vial, Iron Peptide Research label
Longevity & Mitochondrial

NAD+

Also known as Nicotinamide adenine dinucleotide, β-NAD, NAD

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells, used in redox reactions and consumed by sirtuins, PARPs, and CD38. Tissue NAD+ levels decline with age, which drives research interest.

Clinical-stage research

Size

3 options
Catalog no.
NJ100
Specification
100mg*10vials
Per kit
10 vials
PricePricing will be published soon

For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.

Overview

NAD+ is a dinucleotide made of nicotinamide mononucleotide and adenosine monophosphate joined through their phosphate groups. Cells make it from tryptophan, from nicotinic acid, or by recycling nicotinamide through the salvage pathway, in which the enzyme NAMPT controls the rate. Studies in rodents and humans report declining tissue NAD+ with age, and restoring NAD+ in model organisms has been linked to improved metabolic and mitochondrial function. Most human trials have used precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NAD+ itself has been examined in small human pharmacokinetic studies.

Class: Redox coenzyme (pyridine nucleotide)

Mechanism of action

How the compound acts, as described in the literature.

  1. Carries electrons as the NAD+/NADH pair in glycolysis, the TCA cycle, and oxidative phosphorylation, linking nutrient breakdown to ATP production.

  2. Serves as a consumed cosubstrate for sirtuins (protein deacylases), poly(ADP-ribose) polymerases involved in DNA repair, and the NAD+ glycohydrolases CD38 and CD157.

  3. Age-related NAD+ decline has been linked to higher CD38 activity, PARP activation driven by DNA damage, and reduced NAMPT-mediated salvage.

  4. Outside cells, NAD+ is broken down by surface enzymes such as CD38 and CD73 into smaller precursors, including NMN, nicotinamide riboside, and nicotinamide, which cells can take up.

Published research

Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.

Evidence & safety

What the research does not show, and the adverse events and regulatory status it reports.

Direct human data on NAD+ are sparse: the infusion pilot included 8 men given NAD+ and 3 controls, reported no adverse events, and tracked metabolites for only 8 hours. Most trials have tested precursors such as NR and NMN, whether raising NAD+ changes aging outcomes in people is unknown, and NAD+ is not an FDA-approved drug. In laboratory studies, NAD+ metabolism drove the pro-inflammatory secretions of senescent cells, which the authors flagged as a possible tumor-promoting concern.

Specifications

All sizes, exactly as catalogued.

Catalog no.ProductSpecificationVials per kit
NJ100NAD+100mg*10vials10
NJ500NAD+500mg*10vials10
NJ1000NAD+1000mg*10vials10

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.

More in Longevity & Mitochondrial